share_log

ISpecimen Reports Positive Results on Next Day Quote Program for Researchers and Providers

ISpecimen Reports Positive Results on Next Day Quote Program for Researchers and Providers

ISpecimen在針對研究人員和提供者的次日報價計劃上取得了積極的結果
newsfile ·  12/13 20:30

Woburn, Massachusetts--(Newsfile Corp. - December 13, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today positive results attributed to its Next Day Quote Program ("NDQ"). This next-day quote service for researchers and providers is tailored to accelerate the biospecimen transaction process and delivers accurate biospecimen sample pricing within 24 hours of receiving the customer request. Next Day Quotes are possible to implement only when the Company knows the supplier's data on their specific capabilities and pricing, as well as understands the customer's requirements.

馬薩諸塞州沃本--(Newsfile Corp. - 2024年12月13日) - iSpecimen Inc.(納斯達克:ISPC)(「iSpecimen」或「公司」)是一個在線全球市場,連接需要用於醫療研究的生物樣本的科學家與醫療樣本提供者網絡,今天宣佈其次日報價計劃(「NDQ」)取得了積極的成果。該次日報價服務爲研究人員和提供者量身定製,以加快生物樣本交易過程,並在收到客戶請求後的24小時內提供準確的生物樣本定價。次日報價的實施只有在公司了解供應商在其特定能力和定價方面的數據,並理解客戶的要求時才有可能。

Recognizing the need for timely access to high-quality biospecimens to advance life science research, iSpecimen had introduced NDQ to offer researchers and providers with swift and accurate sample pricing. From fresh whole blood and prescreened mutation-characterized blocks to an array of clinically collected remnant, banked and prospective biospecimens, most quotes are provided within a day of receiving the inquiry.

iSpecimen認識到及時獲取高質量生物樣本以推動生命科學研究的必要性,推出了NDQ,爲研究人員和提供者提供快速且準確的樣本定價。從新鮮全血和預篩選的突變特徵塊到多種臨床收集的剩餘、儲存和前瞻性生物樣本,大多數報價在收到詢問後的一天內提供。

Since introducing the program in 2023 and the recently completed build of a search tool, quotes can be created within minutes. With this capability, the Company's sales mix has increasingly shifted towards NDQ. In November 2024, 30% of all sales opportunities were Next Day Quotes. Of all quotes that were generated in November 2024, 48% were Next Day Quotes. Meanwhile, the conversion rate was high for Next Day Quotes. 60% of all purchase orders were Next Day Quotes1.

自2023年推出該計劃和最近完成搜索工具的建設以來,報價可以在幾分鐘內創建。憑藉這一能力,公司的銷售組合越來越向NDQ傾斜。在2024年11月,所有銷售機會中有30%是次日報價。在2024年11月生成的所有報價中,有48%是次日報價。同時,次日報價的轉化率很高,60%的所有采購訂單是次日報價。

Leslie Hoyt, Senior Vice President of Operations commented, "Our customers have responded enthusiastically to iSpecimen's Next Day Quote Program. For the first six months of the program, NDQ has consistently yielded strong results, driving an estimated 60% of sales. The data continue to show that if we quote within the next business day, we greatly increase the likelihood of receiving a signed purchase order. Current and future customers respond positively because time matters."

運營高級副總裁Leslie Hoyt評論道:「我們的客戶對iSpecimen的次日報價計劃反應熱烈。在該計劃的前六個月,NDQ始終取得良好的成果,推動了約60%的銷量。數據繼續表明,如果我們在下一個工作日內報價,我們會大大增加收到簽署採購訂單的可能性。當前和未來的客戶積極響應,因爲時間很重要。」

Ms. Hoyt further commented, "We continue to enhance our internal databases and search tools to proactively harvest data, ensuring the viability of Next day Quote program while increasing the frequency with which Next Day Quotes are possible. This offering accelerates our operational timeline and the customer decision journey. Ultimately next day quotes allow researchers and providers to focus on what matters most, and iSpecimen to be a valuable service provider for all customers."

霍伊特女士進一步評論道:"我們繼續增強我們的內部數據庫和搜索工具,以主動收集數據,確保次日報價計劃的可行性,同時增加次日報價的頻率。此產品加快了我們的運營時間線和客戶決策過程。最終,次日報價使研究人員和供應商能夠專注於最重要的事情,也使iSpecimen成爲所有客戶的有價值服務提供者。"

About iSpecimen
iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit .

關於iSpecimen
iSpecimen(納斯達克:ISPC)提供一個在線市場,用於人類生物樣本,連接商業和非營利組織的科學家與能夠接觸所需患者和樣本的醫療保健提供者。專有的基於雲的科技使科學家能夠直觀地在醫院、實驗室、生物材料庫、獻血中心以及其他醫療組織的聯邦合作伙伴網絡中搜索樣本和患者。欲了解更多信息,請訪問。

Forward Looking Statements

前瞻性聲明

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," "believe," "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company's filings with the SEC, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company's forward-looking statements occurs, the Company's business, financial condition and operating results may vary materially from those expressed in the Company's forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

本新聞稿可能包含根據《1933年證券法》第27A節及《1934年證券交易法》第21E節(經修訂)定義的前瞻性陳述。這些前瞻性陳述使用了「可能」、「將」、「期望」、「打算」、「預期」、「相信」、「估計」和「繼續」或類似詞彙的未來或條件動詞。您應仔細閱讀包含這些詞的陳述,因爲它們討論未來期望和計劃,包括未來經營結果或財務狀況的預測或其他前瞻性信息。前瞻性陳述是基於當前期望和假設,對未來事件的預測、規劃及其他陳述,因此受風險和不確定性的影響。許多因素可能使實際未來事件與本新聞稿中的前瞻性陳述有顯著不同,包括但不限於公司向美國證券交易委員會(SEC)提交的文件中包含的風險因素,這些文件可在www.sec.gov上查閱。前瞻性陳述僅在發表之日有效。新的風險和不確定性會隨時間而出現,因此公司無法預測這些事件及其可能對公司的影響。如果公司前瞻性陳述反映的事件和情況發生變化,公司的業務、財務狀況和經營結果可能與公司前瞻性陳述中表達的內容有實質性差異。提醒讀者不要對前瞻性陳述過度依賴,公司不承擔任何義務,且不打算更新或修訂這些前瞻性陳述,無論是由於新信息、未來事件或其他原因。

For further information, please contact:
Investor Contacts
info@ispecimen.com

如需更多信息,請聯繫:
投資者聯繫方式
info@ispecimen.com

_________________________
1 Source: Company analysis using data from internal business analytics and CRM platforms.

_________________________
1 來源:公司分析使用內部業務分析和客戶關係管理平台的數據。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論